Biotech firm launches nutraceuticals unit
Endovasc - a biotechnology company with two cardiovascular drugs approved for final FDA Phase III trials - announced that it has established a new subsidiary, Nutriceutical Development Corporation (NDC), for its potential blockbuster nicotine and/or...